Tang Y, Hu H, Chen S, Hao B, Xu X, Zhu H
Sci Rep. 2025; 15(1):8591.
PMID: 40074806
PMC: 11903666.
DOI: 10.1038/s41598-025-92700-7.
Basmadjian R, Xu Y, Quan M, Lupichuk S, Cheung W, Brenner D
Breast Cancer Res Treat. 2025; .
PMID: 40072699
DOI: 10.1007/s10549-025-07654-1.
Swinnerton K, Fillmore N, Vo A, La J, Elbers D, Brophy M
EClinicalMedicine. 2025; 81:103114.
PMID: 40070694
PMC: 11893359.
DOI: 10.1016/j.eclinm.2025.103114.
Gairing S, Mildenberger P, Gile J, Artusa F, Scheiner B, Leyh C
JHEP Rep. 2025; 7(3):101295.
PMID: 40059970
PMC: 11889551.
DOI: 10.1016/j.jhepr.2024.101295.
DAoust T, Clocchiatti-Tuozzo S, Rivier C, Mishra A, Hachiya T, Grenier-Boley B
Alzheimers Dement. 2025; 21(3):e70014.
PMID: 40042447
PMC: 11881617.
DOI: 10.1002/alz.70014.
An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma.
Dong L, Ma Y, Cao G, Chen D, Dong F, Jiao X
Cancer Immunol Immunother. 2025; 74(4):112.
PMID: 39998564
PMC: 11861846.
DOI: 10.1007/s00262-025-03963-y.
Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.
Gang M, Othus M, Walter R
Cells. 2025; 14(4).
PMID: 39996762
PMC: 11853423.
DOI: 10.3390/cells14040290.
Deciphering key roles of B cells in prognostication and tailored therapeutic strategies for lung adenocarcinoma: a multi-omics and machine learning approach towards predictive, preventive, and personalized treatment strategies.
Zhang J, Hu D, Fang P, Qi M, Sun G
EPMA J. 2025; 16(1):127-163.
PMID: 39991096
PMC: 11842682.
DOI: 10.1007/s13167-024-00390-4.
A telomere-related signature for predicting prognosis and assessing immune microenvironment in osteosarcoma.
Li S, Zhang L, Zhang H
Front Pharmacol. 2025; 15:1532610.
PMID: 39980969
PMC: 11841432.
DOI: 10.3389/fphar.2024.1532610.
A type 1 diabetes prediction model has utility across multiple screening settings with recalibration.
Templeman E, Ferrat L, Parikh H, You L, Triolo T, Steck A
Res Sq. 2025; .
PMID: 39975907
PMC: 11838734.
DOI: 10.21203/rs.3.rs-5773430/v1.
Identification and multi-dimensional validation of mitochondrial permeability transition-driven necrosis-related model to assess the prognosis and immunotherapy value in breast cancer.
Liu J, Wei T, Quan L, Dou M, Yue J, Yuan P
Eur J Med Res. 2025; 30(1):113.
PMID: 39966932
PMC: 11834492.
DOI: 10.1186/s40001-025-02370-4.
B-cell signatures characterize the immune landscape and predict LUAD prognosis via the integration of scRNA-seq and bulk RNA-seq.
Xu K, Han D, Fan Z, Li Y, Liu S, Liao Y
Sci Rep. 2025; 15(1):5453.
PMID: 39953119
PMC: 11828960.
DOI: 10.1038/s41598-025-89213-8.
Recalibrating the kidney failure risk equation for a Mediterranean European population: reducing age and sex inequality.
Bundo-Luque D, Cunillera-Puertolas O, Cobo-Guerrero S, Romano J, Arbiol-Roca A, Dominguez-Alonso J
Front Med (Lausanne). 2025; 11:1497780.
PMID: 39944820
PMC: 11813909.
DOI: 10.3389/fmed.2024.1497780.
Thioredoxin related transmembrane protein 1acts as a prognostic indictor and promotes proliferation and TMZ resistance of lower-grade glioma.
Hui H, Zhou F, Pei S, Zhou W, Shang J, Wang P
Sci Rep. 2025; 15(1):5246.
PMID: 39939413
PMC: 11822014.
DOI: 10.1038/s41598-025-89908-y.
Integration of single-cell and bulk RNA-sequencing data to construct and validate a signature based on NK cell marker genes to predict immunotherapy response and prognosis in colorectal cancer.
Qin X, Xu W, Wu J, Li M
Discov Oncol. 2025; 16(1):134.
PMID: 39920524
PMC: 11805743.
DOI: 10.1007/s12672-025-01842-7.
A new signature associated with anoikis predicts the outcome and immune infiltration in nasopharyngeal carcinoma.
Luo Y, Wei W, Huang Y, Li J, Qin W, Hao Q
Discov Oncol. 2025; 16(1):123.
PMID: 39913001
PMC: 11802990.
DOI: 10.1007/s12672-025-01869-w.
Identification of EARS2 as a Potential Biomarker with Diagnostic, Prognostic, and Therapeutic Implications in Colorectal Cancer.
Wang L, Deng X, Tang J, Gong Y, Bu S, Li Z
Immunotargets Ther. 2025; 14:65-85.
PMID: 39906030
PMC: 11791672.
DOI: 10.2147/ITT.S499680.
Elevated POSTN expression predicts poor prognosis and is associated with radioresistance in cervical cancer patients treated with radical radiotherapy.
Huang C, Xiao W, Yao X, Li Z, He J
Sci Rep. 2025; 15(1):4174.
PMID: 39905145
PMC: 11794688.
DOI: 10.1038/s41598-025-88908-2.
Revealing the limitations of 10-year MACE observations: 20-year observed total cardiovascular burden in the EPIC-Norfolk study.
van Trier T, Snaterse M, Dorresteijn J, Bogaart M, Scholte Op Reimer W, Visseren F
Open Heart. 2025; 12(1).
PMID: 39904556
PMC: 11795405.
DOI: 10.1136/openhrt-2024-002981.
Identification and validation of TSPAN13 as a novel temozolomide resistance-related gene prognostic biomarker in glioblastoma.
Wang H, Liu Z, Peng Z, Lv P, Fu P, Jiang X
PLoS One. 2025; 20(2):e0316552.
PMID: 39903772
PMC: 11793784.
DOI: 10.1371/journal.pone.0316552.